{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:45:50Z","timestamp":1770749150103,"version":"3.50.0"},"reference-count":29,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T00:00:00Z","timestamp":1221004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In 2002, CDC initiated the Anthrax Vaccination Program (AVP) to provide voluntary pre\u2010exposure anthrax vaccination for individuals at high risk for exposure to <jats:italic>Bacillus anthracis<\/jats:italic> spores. The AVP offered an opportunity to investigate hypothesized reasons for a reported gender difference in injection site adverse events (AEs) following anthrax vaccine adsorbed (AVA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate in women the impact of body mass index (BMI), pre\u2010vaccination serum progesterone levels, and pre\u2010vaccination anti\u2010anthrax protective antigen immunoglobulin G concentrations (anti\u2010PA IgG) on the occurrence of AEs following subcutaneous AVA vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Participants' BMI was determined at enrollment. Also, pre\u2010vaccination blood samples were assayed for serum progesterone and anti\u2010PA IgG. Post\u2010vaccination solicited AEs were recorded by participants using a 4\u2010day diary card.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Obese group had an elevated risk for arm soreness. Decreased pre\u2010vaccination serum progesterone level was associated with arm swelling. Increased pre\u2010vaccination anti\u2010PA IgG was associated with itching on the arm; and within the obese group, was associated with arm swelling, lump or knot, redness, soreness, and warmth.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In AVA vaccinated women, obesity was associated with arm soreness and decreased pre\u2010vaccination serum progesterone levels were associated with increased rate of arm swelling. Increased pre\u2010vaccination anti\u2010PA IgG may be associated with an increased frequency of itching on the arm, and in obese women, may increase the occurrence of arm swelling, lump or knot, redness, and warmth. Administering AVA according to a woman's menstrual phase may reduce the occurrence of certain injection site reactions. Copyright \u00a9 2008 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1657","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T09:13:31Z","timestamp":1221038011000},"page":"1060-1067","source":"Crossref","is-referenced-by-count":13,"title":["Evaluation of body mass index, pre\u2010vaccination serum progesterone levels and anti\u2010anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women"],"prefix":"10.1002","volume":"17","author":[{"given":"Yujia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey W.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles E.","family":"Rose Jr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond E.","family":"Biagini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura H.","family":"Franzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry P.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah L.","family":"Sammons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley A.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,9,10]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"Anthrax Vaccine Adsorbed (BIOTHRAX\u2122) Package Insert.2002; Manufactured by Bioport Corporation Lansing Michigan US Lic. No. 1260."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00723-5"},{"key":"e_1_2_1_4_2","volume-title":"The anthrax vaccine. Is it safe? Does it work?","author":"Institute of Medicine","year":"2002"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00462-5"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00387-5"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00435-3"},{"key":"e_1_2_1_8_2","volume-title":"An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program","author":"Institute of Medicine","year":"2002"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1359"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(97)70056-8"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(73)90115-2"},{"key":"e_1_2_1_12_2","first-page":"10","article-title":"Vaccine allergy and pseudo\u2010allergy","volume":"13","author":"Ponvert C","year":"2003","journal-title":"Eur J Dermatol"},{"key":"e_1_2_1_13_2","volume-title":"Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality","author":"Institute of Medicine","year":"1994"},{"key":"e_1_2_1_14_2","first-page":"1","article-title":"Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines","volume":"55","author":"CDC","year":"2006","journal-title":"MMWR"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1302"},{"key":"e_1_2_1_16_2","unstructured":"BMI\u2014Body Mass Index: About BMI for Adults Centers for Disease Control and Prevention:http:\/\/www.cdc.gov\/nccdphp\/dnpa\/bmi\/adult_BMI\/about_adult_BMI.htm(accessed June 26 2007)."},{"key":"e_1_2_1_17_2","unstructured":"ADVIA Centaur ReadyPack and ACS: 180. Bayer Corporation 1998."},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/oem.2003.008565"},{"key":"e_1_2_1_19_2","first-page":"50","article-title":"Comparison of a multiplexed fluorescent covalent microsphere immunoassay and an enzyme\u2010linked immunosorbent assay for measurement of human immunoglobulin G antibodies to anthrax toxins","volume":"11","author":"Biagini RE","year":"2004","journal-title":"Clin Diag Lab Immunol"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.99107s5681"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb07628.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25102"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200319246"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200319451"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540450065037"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7271.1237"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1542\/peds.83.5.679","article-title":"Adverse reactions to diphtheria, tetanus, pertussis\u2010polio vaccination at18 months of age: Effect of injection site and needle length","volume":"83","author":"Ipp MM","year":"1989","journal-title":"Pediatrics"},{"key":"e_1_2_1_28_2","volume-title":"Report of the committee on infectious diseases","author":"American Academy of Pediatrics","year":"1997"},{"key":"e_1_2_1_29_2","first-page":"626","article-title":"Injection granuloma of the buttock","volume":"102","author":"Michaels L","year":"1970","journal-title":"Can Med Assoc J"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archfami.3.2.146"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1657","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1657","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T07:41:49Z","timestamp":1700034109000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,10]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1002\/pds.1657"],"URL":"https:\/\/doi.org\/10.1002\/pds.1657","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,10]]}}}